J&J Talc Charge: $5.5 Billion Hit Wipes Out Q3 Profit as CFO Says 95% Sign-Up Is 'Trending'

The J&J talc charge is $5.519 billion before tax: Johnson & Johnson recorded it in the third quarter of 2026, reported on October 13, to account for its proposed $5.5 billion resolution of roughly 76,000 ovarian cancer claims, and it cut quarterly net earnings to $210 million from $5.152 billion a year earlier. The charge matters to the litigation because a company does not normally book the full value of a deal it expects to fail, and on the same day its chief financial officer told analysts the settlement is "trending to meet the 95% threshold" on which the entire resolution depends.

That pairing (a full accrual plus a public statement on the sign-up count) is the most concrete signal since July 27 that the largest Mass Tort in the federal system is moving toward closure. It is not closure. The deal still has no effective date, no claims administrator has been publicly named, the first dollar is not due until 2027, and the Multidistrict Litigation (MDL) in New Jersey remains frozen rather than dismissed. What follows sets out what the company reported, what the accounting does and does not tell claimants and their lawyers, and how the earnings day fits into the procedural clock that has been running in MDL No. 2738 since September.

How much was the J&J talc charge in Q3 2026?

The pre-tax litigation special item in the third quarter was $5.519 billion, against $15 million in the same quarter of 2025, according to the company's non-GAAP reconciliation as reported by multiple outlets. The figure tracks the $5.5 billion commitment Johnson & Johnson announced on July 27, 2026, and the company attributed the quarter's sharply lower reported results to the proposed talc litigation resolution together with two unrelated items: the acquisition of Firefly Bio and a strategic collaboration with Sail Biomedicines.

That second point explains why some coverage of the J&J talc charge cites a number near $7 billion. Earnings-call summaries describing "approximately $7 billion" of special charges are adding the deal-related costs to the talc accrual. The talc-only figure is the $5.519 billion litigation line, and that is the number that bears on claimants.

Metric (Q3 2026)	Reported	Q3 2025 comparison
Worldwide sales	$25.4 billion (+5.9%)	—
Pre-tax litigation special item	$5.519 billion	$15 million
Net earnings (GAAP)	$210 million	$5.152 billion
Diluted EPS (GAAP)	$0.09	$2.12
Adjusted EPS (excludes special items)	$2.59	down about 7.5% year on year
Full-year 2026 adjusted EPS guidance	raised $0.06 to $11.10 at midpoint	—
Full-year 2026 sales outlook	about $101.2 billion	—

Net earnings fell roughly 96%. Adjusted figures, which strip out the litigation charge and the deal costs, beat analyst consensus, and the company raised full-year guidance. The market still reacted to the headline: 24/7 Wall St. reported the stock down about 5% on October 13, and other trading desks put the session's decline closer to 5.7%, with weaker MedTech growth (about 2.5%) cited alongside the charge.

Why did J&J's profit fall in the third quarter of 2026?

Because the company took the talc settlement onto its income statement in a single quarter. Under US accounting rules for loss contingencies, a company accrues a liability when a loss is probable and the amount can be reasonably estimated. Johnson & Johnson's ovarian talc exposure had been carried for years at a much smaller present-value reserve; its Form 10-Q for the second quarter of 2026 put the total present value of the reserve for talc-related matters at approximately $3.7 billion, as reported in coverage of that filing. The third-quarter charge is a separate and larger hit to earnings on top of that history.

The company has not published, in anything surfaced so far, a reconciliation showing how the new charge and the old reserve combine on the balance sheet. That detail should appear in the Form 10-Q for the quarter ended in late September, which is due in the coming weeks. Until then, the defensible statement is the narrow one: Johnson & Johnson recognized $5.519 billion of pre-tax litigation expense in the quarter, and the company itself ties that expense to the ovarian resolution.

None of this is an admission of liability. The July 27 announcement repeated the company's position that its talc products are safe and do not cause cancer, and the earnings materials frame the charge as the cost of a proposed resolution, not a concession on causation.

Is the J&J talc settlement final?

No. The J&J talc settlement is a proposal that takes effect only if lead plaintiff firms representing at least 95% of the remaining ovarian claims expressly agree to participate. As of October 13, 2026, the company had not announced that the condition was satisfied. Its prepared remarks repeated the condition and added a single sentence of status.

That status line is the news inside the earnings release. CFO Joseph Wolk's prepared remarks state the condition, that the $5.5 billion ovarian resolution requires the express participation of at least 95% of the remaining ovarian claims, and then say: "We are trending to meet the 95% threshold." CFO Dive and transcript services carried the same wording from the Tuesday call.

The sentence is carefully drawn. "Trending to meet" is not "have met." It does not disclose a percentage, a count of participating firms, or a date by which the company expects to declare the condition satisfied or waive it. It is, however, a statement made to investors in a context where securities-law disclosure obligations attach, and it is the first public characterization of the sign-up count from either side since the court began requiring participation reports in September.

Has J&J reached 95% participation in the talc settlement?

Not publicly. What exists is the company's statement that participation is trending toward the threshold, plus a court-ordered reporting process that runs on a two-week cycle. The District of New Jersey, where the federal talc cases are centralized before Judge Michael A. Shipp, has held the deadlines in MDL No. 2738 in abeyance and directed Negotiation Counsel to file updates on claimant communications, claimant participation and the settlement process beginning September 15, 2026 and every two weeks after that until the court orders otherwise.

Those updates are the closest thing to a public scoreboard. They have not, in any reporting surfaced for this article, disclosed a percentage. The earnings call therefore did something the docket has not yet done: it put a directional statement on the record.

Two features of the threshold explain why "trending" is plausible and also why it is not the same thing as done.

• The count is firm-level. Participation is defined by the express agreement of lead plaintiff firms on behalf of the claims they hold, not by individual ballots from 76,000 households. A small number of large inventory holders can move the percentage quickly once they commit.
• Individual consent still sits underneath it. Aggregate settlement rules require informed consent from each client before a lawyer resolves multiple clients' claims on a collective basis. A firm can sign; it then has to deliver its clients' individual acceptances of the Settlement Matrix values. Five percent of about 76,000 is roughly 3,800 claims, so a modest pocket of holdouts can still matter.

When will talc claimants be paid?

Not before 2027, and only if the deal closes. The terms Johnson & Johnson filed on July 27, 2026 cap the first payment at no more than $3 billion in 2027, with no further payments due before 2028. The third-quarter charge does not change that schedule; an accrual is an accounting entry, not a transfer of cash to a Qualified Settlement Fund (QSF).

Several practical steps also have to happen before money moves to an individual claimant, and none has been publicly completed:

Step	Status as of October 15, 2026
95% participation condition satisfied or waived	Not announced; company says "trending to meet"
Claims Administrator publicly named	Not announced in public reporting
Per-claim matrix values disclosed	Not published; point-based matrix described in reporting
Individual client consents collected	Ongoing within participating firms
First payment (capped at $3 billion)	Scheduled for 2027
Further payments	None due before 2028

Reporting since July has described a point-based Settlement Matrix without a ceiling on the aggregate. Christopher Seeger, who helped negotiate the deal for plaintiffs, has been reported as estimating that total payments could exceed $7 billion. That estimate sits uneasily with a $5.519 billion accrual only if the accrual is read as a cap. It is better read as the company's best estimate of the probable cost today; the eventual total depends on how many claims qualify and how they score.

Does the J&J talc settlement cover mesothelioma claims?

No. The proposed resolution covers ovarian cancer claims only. Mesothelioma claims, which allege asbestos contamination in talc and are tried under different proof in different courtrooms, are outside it, and so are claims not yet on file. The third-quarter charge is accordingly an ovarian number. It does not retire the mesothelioma docket, where Johnson & Johnson continues to face individual trials and has absorbed large verdicts, including a $45 million mesothelioma award that an Illinois appeals court has upheld.

The exclusion of future claims is the structural price of resolving the litigation in the tort system rather than in bankruptcy. A Section 524(g) Trust with a channeling injunction can bind people who have not yet been diagnosed. A negotiated inventory deal cannot. Johnson & Johnson tried the bankruptcy route three times through a Texas Two-Step; the third attempt, Red River Talc LLC, ended on March 31, 2025, when Judge Christopher Lopez of the Bankruptcy Court for the Southern District of Texas denied confirmation and dismissed the case. The July 2026 proposal, and now the October accrual, are the consequences of that dismissal.

What happens to MDL 2738 if the talc settlement fails?

The abeyance lifts and the litigation resumes in a weaker posture for claimants than the one they occupied a year ago. The Judicial Panel on Multidistrict Litigation (JPML) reported 69,340 actions pending in MDL No. 2738 on October 1, 2026, up from 69,250 a month earlier. That makes it the largest active MDL in the federal system.

The key pending event is a show-cause order. On July 22, 2026, Magistrate Judge Rukhsanah L. Singh directed ovarian talc plaintiffs to show why their remaining claims should not be dismissed for inability to prove Specific Causation. The order followed the withdrawal of plaintiffs' specific-causation experts in bellwether cases. Plaintiffs' response is due November 19, 2026. If the deal closes first, that response becomes largely academic for participating claims. If it does not, the docket returns to a Daubert Challenge posture on the element that decides individual cases, separate from General Causation, with no identified expert support.

That sequence is why the accrual date matters. Johnson & Johnson took a $5.5 billion charge roughly five weeks before the show-cause deadline. A company that thought the deal likely to collapse would have reasons to wait for the November filing. Booking it now is consistent with management's view that the threshold will be met, though the company has not said so in those terms, and the inference should be held loosely until a participation figure is filed.

Does the talc charge mean J&J will pay more than $5.5 billion?

Not on the record so far. The charge, at $5.519 billion pre-tax, is essentially the committed figure. Three things could push the eventual cost above it: a matrix that scores more qualifying claims or higher values than projected; growth in the ovarian inventory before the participation cutoff, since 76,000 was the company's July count while the federal docket alone keeps rising; and the mesothelioma docket, which no ovarian accrual covers. Conversely, a deal that closes with fewer qualifying claims could cost less. Investors and claimants should watch for any adjustment in the fourth-quarter results.

What the J&J talc charge means for plaintiffs' firms, claimants and defendants

For plaintiffs' firms holding ovarian inventory. The CFO's statement increases pressure on holdouts. Firms that have not committed are now negotiating against a counterparty that has told the market the threshold is within reach and has already absorbed the cost. The firm-level structure also means that client-consent workflows, lien resolution and Medical Lien clearance should be ready before a declaration of effectiveness, not after. Contingency Fee and Common Benefit Fund assessments will be applied against matrix values that have not yet been published.

For individual claimants. The accrual does not change what any one person receives or when. Payments remain scheduled to begin no earlier than 2027. Claimants represented by firms that participate are on the settling side of the count by virtue of that firm's decision, but each client still has to consent to the individual offer. Claimants whose counsel declines face the November 19 show-cause response and the specific-causation problem that produced it.

For mesothelioma claimants and their counsel. Nothing in the third-quarter charge resolves asbestos-contamination claims. The trial calendar on that side of the litigation continues.

For other mass-tort defendants. The talc deal is now a working template for an MDL exit outside bankruptcy: secure a causation ruling or expert withdrawal, offer an uncapped matrix conditioned on near-total participation, stretch the cash over several years, and accrue once the sign-up trend is favorable. Defendants in other large dockets, including companies contending with their own talc exposure, will read the earnings-day disclosure as evidence that the structure can carry a 95% condition.

For funders and investors in claim portfolios. A first payment in 2027 and no further payments before 2028 mean that Third-Party Litigation Funding returns on ovarian talc inventory depend on duration as much as on matrix values.

Timeline: the ovarian talc endgame

Date	Event
March 31, 2025	Red River Talc LLC bankruptcy dismissed; third Texas Two-Step attempt fails
July 22, 2026	Magistrate Judge Singh issues show-cause order on specific causation in MDL 2738
July 27, 2026	J&J announces $5.5 billion ovarian resolution conditioned on 95% participation
September 15, 2026	First biweekly Negotiation Counsel participation report due; deadlines held in abeyance
October 1, 2026	JPML reports 69,340 actions pending in MDL 2738
October 13, 2026	J&J reports $5.519 billion Q3 litigation charge; CFO says threshold is "trending"
November 19, 2026	Plaintiffs' show-cause response due if litigation resumes
2027	First payment, capped at $3 billion, if the deal closes
2028 onward	Remaining payments

FAQ

How much was J&J's talc charge?

Johnson & Johnson recorded a pre-tax litigation special item of $5.519 billion in the third quarter of 2026, reported October 13, tied to the proposed $5.5 billion resolution of ovarian talc claims.

Why did J&J's profit drop in Q3 2026?

Net earnings fell to $210 million, or $0.09 per diluted share, because the talc charge and costs related to the Firefly Bio acquisition and the Sail Biomedicines collaboration were recognized in the quarter; adjusted EPS of $2.59 excludes them.

Is the J&J talc settlement final?

No. It takes effect only if lead plaintiff firms holding at least 95% of remaining ovarian claims expressly participate; on October 13, 2026 the CFO said the company is "trending to meet" that threshold but did not say it had been met.

When will talc claimants be paid?

If the deal closes, the first payment, capped at $3 billion, is scheduled for 2027, with no further payments due before 2028.

Are mesothelioma talc claims included?

No. The proposed resolution and the related charge cover ovarian cancer claims only; mesothelioma claims and claims not yet on file are excluded.

What happens if participation falls short of 95%?

The agreement does not take effect, the abeyance in MDL No. 2738 would be expected to lift, and plaintiffs would have to answer the July 22, 2026 show-cause order on specific causation, with a response due November 19, 2026.